Drug Profile
Oracin
Alternative Names: Oracine; VUFB 16956Latest Information Update: 14 Apr 2010
Price :
$50
*
At a glance
- Originator VUFB
- Developer Synthesia; Zentiva
- Class Antineoplastics; Ethanolamines; Isoquinolines; Small molecules
- Mechanism of Action DNA inhibitors; Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 15 Sep 2003 Leciva has merged with Slovakofarma to form Zentiva
- 14 Feb 2002 Profile reviewed and compound appears to be in active development
- 15 Feb 2001 Phase-II clinical trials for Cancer in Czech Republic (IV)